ACTRN12619001348145已完成未知
The pharmacokinetics and safety of metformin in patients with liver disease and diabetes already treated with metformin
St Vincent's Hospital, Sydney0 个研究点目标入组 34 人开始时间: 2019年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients with chronic liver disease who are being treated with metformin for their type 2 diabetes mellitus.
排除标准
- •No exclusion criteria.
研究者
相似试验
已完成
4 期
The safety and disposition of metformin in people with liver diseaseChronic liver diseaseMetabolic and Endocrine - DiabetesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12619001292167St Vincent's Hospital, Sydney24
已完成
不适用
A study of factors affecting the concentrations of metformin in type 2 diabetic patientsType 2 diabetesMetabolic and Endocrine - DiabetesACTRN12611000908932Prof Richard Day120
招募中
4 期
Can metformin be safely used in patients with heart failure?Cardiovascular - Other cardiovascular diseasesChronic heart failureACTRN12617001418369St Vincent's Hospital Sydney50
终止
4 期
Can metformin be used safely in dialysis patients?Renal and Urogenital - Kidney diseaseType 2 diabetes mellitusEnd stage kidney disease.Metabolic and Endocrine - DiabetesACTRN12616000675426St Vincent's Hospital Sydney80
已完成
不适用
Pharmacokinetics and Pharmacodynamics of metformin in patients with type 2 diabetes and renal impairmentDiabetic NephropathyNL-OMON38577niversitair Medisch Centrum Groningen110